ADVA Biotechnology Overview
ADVA Biotechnology develops enabling technologies for cell therapy manufacturing. The company has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution. ADVA X3 enables autologous cell therapy manufacturing at the bedside, allowing optimization, tight quality assurance, improved availability, reduced time to market, and significant cost reduction. The automated platform is designed to enable autologous manufacturing of additional types of cells with a change in the disposable chamber, allowing efficiency and flexibility with a long pipeline of products.
Cumulative Funding Raised Over Time ($)
Latest News
Lonza and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza's Patents | Company Insight
growth-positive
https://www.jpost.com/health-science/personalized-cancer-treatments-no-longer-a-dream-with-new-medical-tech-655399
ADVA Biotechnology has developed the ADVA X3, a device that can create CAR-T cells, a partial cure for certain types of cancer. The device automates the process of producing CAR-T cells, making it more accessible and cost-effective. Currently, the treatment is only available to a small group of terminally ill cancer patients due to cost, logistics, and lack of technology. The ADVA X3 aims to revolutionize the industry by allowing hospitals to produce customized drugs for each patient, reducing manufacturing costs, and increasing accessibility. ADVA Biotechnology has received positive feedback from medical professionals, industry leaders, and investors, and plans to introduce the device into hospitals and medical centers in Israel and internationally.
CustomersInvestment
growth-positive
https://www.jpost.com/health-science/adva-biotechnology-643385
ADVA Biotechnology has developed solutions for manufacturing personalized cell therapy for specific patients at bedside. The founder and CEO, Dr. Ohad Karnieli, spoke about the revolutionary change in medicine through personalized medicine and the need for enabling technology to bring it to patients in a cost-efficient manner.
Customers
growth-positive
Orgenesis and Adva Biotechnology to Develop and Distribute Advanced Automated Culturing System for Cell Therapy Manufacturing
Orgenesis Inc. has entered into an agreement with Adva Biotechnology Ltd. for the development of an automated culturing system for use in contract manufacturing services and therapeutic development. The system has the potential to enable cost-efficient and automated manufacturing for autologous cell therapies. Orgenesis intends to develop this technology through its joint venture with Atvio Biotech Ltd. and distribute the systems globally through MaSTherCell and its CDMO partners. The collaboration will be financed by Orgenesis and is part of their commitment to innovation in the field of autologous cell therapies. The system is designed to allow single-use, closed end-to-end automated manufacturing of suspension cells. Once fully developed, the system should significantly reduce costs and enhance manufacturing capacity for cell therapy companies.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $385K |
| Last funding | $385K |
| Stage | Seed |
| Rounds | 3 |
| Investors | 2 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | www.advabio.com/ |
| Careers | Careers page |
Locations
Bar Lev Industrials Park, Israel
Photos & Videos
3 item(s)
